$210 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 33 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 85.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $27,999,000 | +4.8% | 2,944,201 | -2.5% | 13.31% | -34.7% |
| KDMN | Buy | KADMON HLDGS INC | $20,156,000 | +28.6% | 7,635,000 | +1.3% | 9.58% | -19.9% |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $14,974,000 | -7.9% | 760,500 | +5.8% | 7.12% | -42.6% |
| CASM | CAS MED SYS INC | $12,790,000 | +51.9% | 5,263,508 | 0.0% | 6.08% | -5.3% | |
| INSM | New | INSMED INC | $10,756,000 | – | 370,000 | +100.0% | 5.11% | – |
| BHVN | Buy | BIOHAVEN PHARMACTL HLDG CO L | $10,603,000 | +52.9% | 206,000 | +9.9% | 5.04% | -4.7% |
| IMMU | Buy | IMMUNOMEDICS INC | $9,605,000 | +68.3% | 500,000 | +25.0% | 4.57% | +4.9% |
| VCYT | Sell | VERACYTE INC | $9,545,000 | +71.5% | 381,500 | -13.8% | 4.54% | +6.9% |
| DERM | New | DERMIRA INC | $8,625,000 | – | 636,500 | +100.0% | 4.10% | – |
| ARGX | Buy | ARGENX SEsponsored adr | $7,927,000 | +55.7% | 63,500 | +19.8% | 3.77% | -3.0% |
| CBAY | New | CYMABAY THERAPEUTICS INC | $6,872,000 | – | 517,500 | +100.0% | 3.27% | – |
| VRAY | Buy | VIEWRAY INC | $6,023,000 | +218.5% | 815,000 | +161.6% | 2.86% | +98.6% |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $5,881,000 | +72.1% | 205,500 | +18.8% | 2.80% | +7.3% |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $5,827,000 | – | 61,000 | +100.0% | 2.77% | – |
| XENE | Buy | XENON PHARMACEUTICALS INC | $5,613,000 | +65.5% | 552,500 | +2.8% | 2.67% | +3.2% |
| IRIX | IRIDEX CORP | $5,356,000 | -3.0% | 1,174,500 | 0.0% | 2.55% | -39.5% | |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $4,817,000 | – | 328,825 | +100.0% | 2.29% | – |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $4,816,000 | – | 919,000 | +100.0% | 2.29% | – |
| ARVN | New | ARVINAS INC | $4,635,000 | – | 314,000 | +100.0% | 2.20% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $4,242,000 | – | 337,500 | +100.0% | 2.02% | – |
| ALEC | New | ALECTOR INC | $3,744,000 | – | 200,000 | +100.0% | 1.78% | – |
| ACER | Buy | ACER THERAPEUTICS INC | $3,572,000 | +24.2% | 147,000 | +2.8% | 1.70% | -22.6% |
| ARWR | New | ARROWHEAD PHARMACEUTICALS IN | $3,074,000 | – | 167,500 | +100.0% | 1.46% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $3,005,000 | – | 41,000 | +100.0% | 1.43% | – |
| BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO Lcall | $2,574,000 | +29.3% | 50,000 | -7.1% | 1.22% | -19.4% |
| QTNT | New | QUOTIENT LTD | $2,523,000 | – | 280,000 | +100.0% | 1.20% | – |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $1,817,000 | -69.5% | 87,500 | -80.0% | 0.86% | -81.0% |
| GOSS | New | GOSSAMER BIO INC | $1,300,000 | – | 60,000 | +100.0% | 0.62% | – |
| ALLK | New | ALLAKOS INC | $547,000 | – | 13,500 | +100.0% | 0.26% | – |
| STRO | SUTRO BIOPHARMA INC | $518,000 | +26.3% | 45,500 | 0.0% | 0.25% | -21.4% | |
| CEMI | Sell | CHEMBIO DIAGNOSTICS INC | $231,000 | -89.5% | 41,667 | -89.2% | 0.11% | -93.4% |
| BCRX | BIOCRYST PHARMACEUTICALS | $204,000 | +1.0% | 25,000 | 0.0% | 0.10% | -37.0% | |
| NVAX | New | NOVAVAX INCput | $138,000 | – | 250,000 | +100.0% | 0.07% | – |
| OTLK | Exit | OUTLOOK THERAPEUTICS INC | $0 | – | -29,082 | -100.0% | -0.01% | – |
| IMMU | Exit | IMMUNOMEDICS INCput | $0 | – | -400,000 | -100.0% | -4.35% | – |
| XBI | Exit | SPDR SERIES TRUSTput | $0 | – | -100,000 | -100.0% | -5.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.